[ANIK] Anika Therapeutics Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 49.53 Change: 0.9 (1.85%)
Ext. hours: Change: 0 (0%)

chart ANIK

Refresh chart

Strongest Trends Summary For ANIK

ANIK is in the long-term up 332% in 15 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair in the United States, Europe, and internationally. The company?s products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, and MONOVISC for the treatment of osteoarthritis of the knee and joints; Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells that is used in connection with soft tissue regeneration; Hyalonect, a woven gauze used as a graft wrap; Hyaloss used to mix blood/bone grafts to form a paste for bone regeneration; and Hyaloglide, an ACP gel used in tenolysis treatment. The company?s dermal products include wound care products that comprise Hyalomatrix and Hyalofill, for treatment of complex wounds, such as burns and ulcers; Hyalograft 3D and Laserskin scaffolds for use in connection with the regen

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS2.07 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -40.93% Sales Growth - Q/Q-33.26% P/E21.89
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA13.56% ROE14.74% ROI
Current Ratio23.7 Quick Ratio21.67 Long Term Debt/Equity Debt Ratio0.03
Gross Margin76.03% Operating Margin49.46% Net Profit Margin30.77% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.9 M Cash From Investing Activities-6.01 M Cash From Operating Activities3.98 M Gross Profit17.63 M
Net Profit7.82 M Operating Profit12.43 M Total Assets208.01 M Total Current Assets155.73 M
Total Current Liabilities7.96 M Total Debt Total Liabilities17.44 M Total Revenue22.9 M
Technical Data
High 52 week68.43 Low 52 week30.16 Last close33.37 Last change-1.68%
RSI28.12 Average true range1.5 Beta0.55 Volume53.19 K
Simple moving average 20 days-12.46% Simple moving average 50 days-5.2% Simple moving average 200 days-30.71%
Performance Data
Performance Week-15.56% Performance Month-8.45% Performance Quart-24.07% Performance Half-50.76%
Performance Year-35.45% Performance Year-to-date-0.71% Volatility daily3.96% Volatility weekly8.86%
Volatility monthly18.15% Volatility yearly62.89% Relative Volume229.99% Average Volume131.63 K
New High New Low

News

2019-11-15 10:02:03 | VistaGen's VTGN Major Depressive Disorder Drug Disappoints

2019-11-15 09:10:02 | Amarin AMRN Gets FDA Panel Nod for Vascepa Label Expansion

2019-11-15 08:57:01 | Sarepta SRPT Stock Down Despite New $48M Gene Therapy Deal

2019-11-15 08:30:00 | Anika Therapeutics Announces Participation in MEDICA International Trade Fair and International Cartilage Regeneration and Joint Preservation Society Focus Meeting

2019-11-14 10:20:03 | BioDelivery BDSI Stock Up on Q3 Earnings Beat & Raised View

2019-11-14 09:00:02 | QIAGEN QGEN Catches Eye: Stock Jumps 9.9%

2019-11-14 08:27:01 | Halozyme Therapeutics HALO Looks Good: Stock Adds 5.4% in Session

2019-11-13 09:05:02 | Catalyst's CPRX Q3 Earnings Beat Estimates, Sales Miss

2019-11-13 08:00:01 | IVERIC bio ISEE Q3 Loss Narrows Y/Y, Zimura Advancing Well

2019-11-12 09:52:02 | Amicus' FOLD Shares Rise on Q3 Earnings & Revenue Beat

2019-11-09 15:54:06 | Here is What Hedge Funds Think About Anika Therapeutics, Inc. ANIK

2019-11-08 10:08:03 | Spectrum Pharma's SPPI Q3 Loss Narrows, Focus on Rolontis

2019-11-07 11:26:04 | PDL BioPharma PDLI Q3 Earnings Beat, LENSAR Drives Sales

2019-11-07 11:20:04 | Emergent EBS Beat Earnings in Q3, Vaccines Drive Sales

2019-11-06 11:24:04 | Blueprint Medicines BPMC Q3 Earnings & Sales Top Estimates

2019-11-05 16:05:00 | Anika to Showcase Joint Preservation and Restoration Portfolio at the 2019 Fortius International Sports Injury Conference

2019-11-05 11:45:04 | Acorda ACOR Q3 Earnings and Revenues Surpass Estimates

2019-11-04 11:18:04 | AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates

2019-11-04 11:08:04 | The Zacks Analyst Blog Highlights: Unifi, BioDelivery Sciences International, Crocs, Anika Therapeutics and Plexus

2019-11-04 05:56:11 | Does Anika Therapeutics, Inc. NASDAQ:ANIK Have A High Beta?

2019-11-01 14:49:06 | Repligen RGEN Beats on Q3 Earnings, Lifts 2019 Guidance

2019-11-01 07:45:11 | 5 Top Momentum Stocks in October That Still Have Upside Left

2019-10-31 12:40:04 | Immunomedics IMMU Reports Wider-Than-Expected Loss in Q3

2019-10-31 12:33:04 | Vertex VRTX Q3 Earnings Beat, Revenues Lag Estimates

2019-10-30 10:00:02 | What Makes Anika Therapeutics ANIK a Strong Momentum Stock: Buy Now?

2019-10-29 10:27:02 | Anika Therapeutics, Inc. ANIK Shares March Higher, Can It Continue?

2019-10-25 07:12:03 | The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug

2019-10-24 18:45:10 | Anika Therapeutics ANIK Q3 Earnings and Revenues Surpass Estimates

2019-10-24 16:05:00 | Anika Reports Third Quarter 2019 Financial Results

2019-10-18 11:17:03 | Zacks.com featured highlights include: KB Home, Crocs, NetEase, Taylor Morrison Home and Anika Therapeutics

2019-10-17 10:33:02 | Analysts Estimate Anika Therapeutics ANIK to Report a Decline in Earnings: What to Look Out for

2019-10-17 07:24:11 | 5 Stocks With Recent Price Strength Despite Trade Jitters

2019-10-16 08:30:00 | Anika to Showcase Joint Preservation and Restoration Portfolio at the Annual Scientific Meeting of the International Society for Hip Arthroscopy

2019-10-14 08:30:00 | Anika Appoints Mira Leiwant as Vice President of Regulatory Affairs, Quality, and Clinical Affairs

2019-10-10 16:05:00 | Anika to Issue Third-quarter 2019 Financial Results and Business Highlights on Thursday, October 24

2019-10-04 08:52:12 | Constellation Pharmaceuticals CNST Looks Good: Stock Adds 8.3% in Session

2019-10-04 08:30:00 | Anika to Showcase Joint Preservation and Restoration Portfolio at the 2019 World Congress of the International Cartilage Regeneration and Joint Preservation Society

2019-10-03 08:41:12 | Axsome AXSM Catches Eye: Stock Jumps 9.3%

2019-10-03 08:39:12 | AnaptysBio ANAB Looks Good: Stock Adds 8.1% in Session

2019-10-03 08:37:12 | Apellis Pharmaceuticals APLS Catches Eye: Stock Jumps 5.2%

2019-09-30 16:50:27 | 5 Companies With Positive Earnings Growth Estimates

2019-09-29 08:50:44 | If You Had Bought Anika Therapeutics NASDAQ:ANIK Shares Five Years Ago You'd Have Made 41%

2019-09-26 20:30:00 | Link to Amazon Could Boost Semtech Shares

2019-09-26 09:30:01 | Has Anika Therapeutics ANIK Outpaced Other Medical Stocks This Year?

2019-09-26 09:00:01 | Anika ANIK Upgraded to Strong Buy: What Does It Mean for the Stock?

2019-09-26 08:35:12 | Why Avid Bioservices CDMO Could Be Positioned for a Slump

2019-09-18 08:30:00 | Anika Commences U.S. Commercial Launch of TACTOSET Bone Repair Therapy Under Its New U.S. Hybrid Commercial Model

2019-09-04 16:05:00 | Anika Therapeutics to Host Analyst and Investor Day on September 18, 2019

2019-09-03 16:05:00 | Anika to Participate in the 2019 Morgan Stanley Global Healthcare Conference on September 10, 2019

2019-08-23 14:12:19 | Here's What Anika Therapeutics, Inc.'s NASDAQ:ANIK P/E Is Telling Us